Supplementary Table 3.
Sensitivity analysis of 24-h SBP at 6 months
| Clinical trials | Number of patients (R/C) | Pooled effect size in mmHg (95% CI) | I2 (%) | Phet | Pz |
|---|---|---|---|---|---|
| All trials pooled | 558/404 | −1.10 (−4.70, 2.50) | 67 | 0.002 | 0.55 |
| Excluded trial | |||||
| DENERHTN | 510/351 | −0.29 (−4.28, 3.71) | 68 | 0.003 | 0.89 |
| DENERVHTA | 547/391 | −2.67 (−5.25, −0.10) | 36 | 0.14 | 0.04 |
| OSLO | 549/394 | −2.10 (−5.48, 1.27) | 62 | 0.01 | 0.22 |
| Prague-15 | 506/350 | −1.06 (−5.18, 3.07) | 71 | 0.001 | 0.62 |
| ReSET | 523/371 | −1.00 (−5.02, 3.02) | 71 | 0.001 | 0.63 |
| SYMPLICITY HTN-2 | 538/379 | −0.51 (−4.29, 3.27) | 69 | 0.002 | 0.79 |
| SYMPLICITY HTN-3 | 229/242 | −0.64 (−5.22, 3.93) | 71 | 0.001 | 0.78 |
| SYMPLICITY HTN-Japan | 536/385 | −6.14 (−12.93, 0.65) | 69 | 0.002 | 0.84 |
| SYMPLICITY-FLEX | 526/369 | −0.56 (−4.77, 3.65) | 71 | 0.0001 | 0.79 |
SBP: Systolic blood pressure; CI: Confidence interval; C: Control group; Phet: Significance for the heterogeneity test; Pz: Significance for the pooled effect size; R: Renal denervation group.